Start page Newsroom All news Newsroom type All Releases Articles year All years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel 12/19/2024 Stock exchange release Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel 12/19/2024 Stock exchange release Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics 12/18/2024 Press release Pathways to the pharmaceutical industry – This is how Orion encourages young people to find their place 12/13/2024 We are Orion Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction 12/12/2024 Stock exchange release Orion’s Nordic pharmaceutical production means security for all of Europe 12/2/2024 Orion and Society More than just tremors – What we should understand about Parkinson’s disease 11/27/2024 Your Health 142,701 Orion Corporation A shares converted into B shares 11/27/2024 Stock exchange release Orion Research Foundation grants EUR 1,109,000 for research in 2025 11/22/2024 Press release Can we treat cancer by activating the body’s own defence system? 11/21/2024 Science and Partnering Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies 11/19/2024 Press release Shattering the silence: menopause awareness as key to more inclusive work environments 11/12/2024 Orion and Society Päivi Kuoppamäki was diagnosed with COPD at the age of 40: “I avoid situations where I might start laughing” 11/4/2024 Your Health Orion Corporation: Managers’ transactions – Henrik Stenqvist 11/1/2024 Managers transactions 18-year-old Pyry shadowed the SVP for R&D for a day – “I would love to do socially significant work” 10/30/2024 Orion and Society Orion Group Interim Report January–September 2024 10/29/2024 Stock exchange release Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule 10/24/2024 Stock exchange release Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 10/15/2024 Press release